Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups

References

• Arvanitis M, Lowenstein CJ. Dyslipidemia. Ann Intern Med. 2023 Jun;176(6):ITC81–ITC96. doi: 10.7326/AITC202306200
   PubMed Web of Science ®Google Scholar
• Pirillo A, Casula M, Olmastroni E, et al. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021 Oct;18(10):689–700. doi: 10.1038/s41569-021-00541-4
   PubMed Web of Science ®Google Scholar
• Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers.2019 Aug 16;5(1):56. doi: 10.1038/s41572-019-0106-z
   PubMedGoogle Scholar
• Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017 Jul;14(7):401–411. doi: 10.1038/nrcardio.2017.31
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014 Dec 4;13(1):159. doi: 10.1186/s12933-014-0159-y
   PubMedGoogle Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019 [2019 Sep 10];140(11):e596–e646. doi: 10.1161/CIR.0000000000000678
   PubMed Web of Science ®Google Scholar
• Muscoli S, Ifrim M, Russo M, et al. Current options and future perspectives in the treatment of dyslipidemia. J Clin Med. 2022 Aug 12;11(16):4716. doi: 10.3390/jcm11164716
   PubMed Web of Science ®Google Scholar
• Posner J, Barrington P, Brier T, et al. Monoclonal Antibodies: Past, Present and Future. Handb Exp Pharmacol. 2019;260:81–141. doi: 10.1007/164_2019_323
   PubMedGoogle Scholar
• Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019 Dec;7(6):e00535. doi: 10.1002/prp2.535
   PubMed Web of Science ®Google Scholar
• Mercep I, Strikic D, Sliskovic AM, et al. New therapeutic approaches in treatment of dyslipidaemia—A narrative review. Pharmaceuticals (Basel). 2022 Jul 7;15(7):839. doi: 10.3390/ph15070839
   PubMedGoogle Scholar
• Atherosclerosis, Coronary Heart Disease Working Group of Chinese Society of C, Editorial Board of Chinese Journal of C. [Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Apr 24;48(4):280–286. doi: 10.3760/cma.j.cn112148-20200121-00036
   PubMedGoogle Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2018 [2019 Jun 18];139(25):e1082–e1143. doi: 10.1161/CIR.0000000000000625
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1–87 doi: 10.4158/EP171764.APPGL
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 [2020 Jan 1];41(1):111–188. doi: 10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Kosmas CE, Pantou D, Sourlas A, et al. New and emerging lipid-modifying drugs to lower LDL cholesterol. Drugs Context. 2021;10:1–22. doi: 10.7573/dic.2021-8-3
   Google Scholar
• Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the international lipid expert panel (ILEP). Prog Cardiovasc Dis. 2023 Jul;79:2–11 doi: 10.1016/j.pcad.2023.03.001
   PubMed Web of Science ®Google Scholar
• Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med.2023 Apr 13;388(15):1353–1364. doi: 10.1056/NEJMoa2215024
   PubMed Web of Science ®Google Scholar
• Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA.2023 Jul 11;330(2):131–140. doi: 10.1001/jama.2023.9696
   PubMed Web of Science ®Google Scholar
• Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu Rev Med. 2018 Jan 29;69(1):133–145. doi: 10.1146/annurev-med-042716-091351
   PubMedGoogle Scholar
• Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016 May;52(2):187–93. doi: 10.1007/s12020-015-0838-9
   PubMed Web of Science ®Google Scholar
• Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med.2012 Mar 22;366(12):1108–18. doi: 10.1056/NEJMoa1105803
   PubMed Web of Science ®Google Scholar
• Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012 Dec 8;380(9858):1995–2006. doi: 10.1016/s0140-6736(12)61771-1
   PubMed Web of Science ®Google Scholar
• Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019 Mar;16(3):155–165. doi: 10.1038/s41569-018-0107-8
   PubMed Web of Science ®Google Scholar
• Lan NSR, Bajaj A, Watts GF, et al. Recent advances in the management and implementation of care for familial hypercholesterolaemia. Pharmacol Res. 2023 Aug;194:106857 doi: 10.1016/j.phrs.2023.106857
   PubMed Web of Science ®Google Scholar
• Reeskamp LF, Nurmohamed NS, Bom MJ, et al. Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis. 2021 Jun;327:13–17. doi: 10.1016/j.atherosclerosis.2021.04.014
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med.2020 Dec 10;383(24):2307–2319. doi: 10.1056/NEJMoa2031049
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017 Jul 20;377(3):296–297. doi: 10.1056/NEJMc1705994
   PubMed Web of Science ®Google Scholar
• Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989 Apr;79(4):733–43. doi: 10.1161/01.cir.79.4.733
   PubMed Web of Science ®Google Scholar
• Waxman S, Ishibashi F, Muller JE. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation. 2006 Nov 28;114(22):2390–411. doi: 10.1161/CIRCULATIONAHA.105.540013
   PubMed Web of Science ®Google Scholar
• Gaba P, Gersh BJ, Muller J, et al. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat Rev Cardiol. 2023 Mar;20(3):181–196. doi: 10.1038/s41569-022-00769-8
   PubMed Web of Science ®Google Scholar
• Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol.2006 Apr 18;47(8 Suppl):C13–8. doi: 10.1016/j.jacc.2005.10.065
   PubMed Web of Science ®Google Scholar
• Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation.2003 Oct 14;108(15):1772–8. doi: 10.1161/01.CIR.0000087481.55887.C9
   PubMed Web of Science ®Google Scholar
• Tomaniak M, Katagiri Y, Modolo R, et al. Vulnerable plaques and patients: state-of-the-art. Eur Heart J. 2020 Aug 14;41(31):2997–3004. doi: 10.1093/eurheartj/ehaa227
   PubMed Web of Science ®Google Scholar
• Drakopoulou M, Toutouzas K, Michelongona A, et al. Statins and vulnerable plaque. Curr Pharm Des. 2017 Oct 19. doi: 10.2174/1381612823666171019161609
   Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA.2004 Mar 3;291(9):1071–80. doi: 10.1001/jama.291.9.1071
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA.2006 Apr 5;295(13):1556–65. doi: 10.1001/jama.295.13.jpc60002
   PubMed Web of Science ®Google Scholar
• Kini AS, Baber U, Kovacic JC, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013 Jul 2;62(1):21–9. doi: 10.1016/j.jacc.2013.03.058
   PubMed Web of Science ®Google Scholar
• Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015 Aug 4;66(5):495–507. doi: 10.1016/j.jacc.2015.05.065
   PubMed Web of Science ®Google Scholar
• Habara M, Nasu K, Terashima M, et al. Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. Am J Cardiol. 2014 Feb 15;113(4):580–7. doi: 10.1016/j.amjcard.2013.10.038
   PubMed Web of Science ®Google Scholar
• Suzuki N, Yokoi T, Kimura T, et al. Risk factors for vulnerable plaque detected using near-infrared spectroscopy in patients receiving statin therapy with No history of coronary artery disease. Int Heart J. 2023;64(4):577–583. doi: 10.1536/ihj.23-011
   PubMed Web of Science ®Google Scholar
• Zhang L, Song K, Zhu M, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Int J Neurosci. 2016 Aug;126(8):675–680. doi: 10.3109/00207454.2015.1057636
   PubMed Web of Science ®Google Scholar
• Stoekenbroek RM, Lambert G, Cariou B, et al. Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol. 2018 Dec;15(1):52–62. doi: 10.1038/s41574-018-0110-5
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100–5. doi: 10.1073/pnas.0402133101
   PubMed Web of Science ®Google Scholar
• Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012 Feb;220(2):381–6. doi: 10.1016/j.atherosclerosis.2011.11.026
   PubMed Web of Science ®Google Scholar
• Ferri N, Marchiano S, Tibolla G, et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis. 2016 Oct;253:214–224. doi: 10.1016/j.atherosclerosis.2016.07.910
   PubMed Web of Science ®Google Scholar
• Ding Z, Pothineni NVK, Goel A, et al. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc Res. 2020 Apr 1;116(5):908–915. doi: 10.1093/cvr/cvz313
   PubMed Web of Science ®Google Scholar
• Giunzioni I, Tavori H, Covarrubias R, et al. Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol. 2016 Jan;238(1):52–62 doi: 10.1002/path.4630
   PubMed Web of Science ®Google Scholar
• Guo Y, Tang Z, Yan B, et al. PCSK9 (proprotein convertase subtilisin/kexin type 9) triggers vascular smooth muscle cell senescence and apoptosis: implication of its direct role in degenerative vascular disease. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):67–86 doi: 10.1161/atvbaha.121.316902
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Schwarz J, Berthold HK. PCSK9 monoclonal antibodies: new developments and their relevance in a nucleic acid-based therapy era. Curr Atheroscler Rep. 2022 Oct;24(10):779–790. doi: 10.1007/s11883-022-01053-3
   PubMed Web of Science ®Google Scholar
• Bellino M, Galasso G, Silverio A, et al. Soluble PCSK9 inhibition: indications, clinical impact, new molecular insights and practical approach—where do we stand? JCM. 2023 Apr 18;12(8):2922. doi: 10.3390/jcm12082922
   Google Scholar
• Ugovsek S, Sebestjen M. Non-lipid effects of PCSK9 monoclonal antibodies on vessel wall. J Clin Med. 2022 Jun 23;11(13):3625. doi: 10.3390/jcm11133625
   PubMed Web of Science ®Google Scholar
• Cao YX, Liu HH, Li S, et al. A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels. Am J Cardiovasc Drugs. 2019 Feb;19(1):87–97. doi: 10.1007/s40256-018-0303-2
   PubMed Web of Science ®Google Scholar
• Watts GF, Chan DC, Somaratne R, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018 Jul 14;39(27):2577–2585. doi: 10.1093/eurheartj/ehy122
   PubMed Web of Science ®Google Scholar
• Watts GF, Chan DC, Pang J, et al. PCSK9 inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). Metabolism. 2020 Jun;107:154221. doi: 10.1016/j.metabol.2020.154221
   PubMed Web of Science ®Google Scholar
• Puccini M, Landmesser U, Rauch U. Pleiotropic effects of PCSK9: focus on thrombosis and Haemostasis. Metabolites. 2022 Mar 4;12(3):226. doi: 10.3390/metabo12030226
   PubMed Web of Science ®Google Scholar
• Blanchard V, Chemello K, Hollstein T, et al. The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors. Cardiovasc Res. 2022 Jul 20;118(9):2103–2111. doi: 10.1093/cvr/cvab247
   PubMed Web of Science ®Google Scholar
• Chang YC, Hsu LA, Ko YL. Exploring PCSK9 genetic impact on lipoprotein(a) via dual approaches: association and Mendelian randomization. Int J Mol Sci. 2023 Sep 28;24(19):14668. doi: 10.3390/ijms241914668
   PubMed Web of Science ®Google Scholar
• Omori H, Ota H, Hara M, et al. Effect of PCSK-9 inhibitors on lipid-rich vulnerable coronary plaque assessed by near-infrared spectroscopy. JACC Cardiovasc Imaging. 2020 Jul;13(7):1639–1641. doi: 10.1016/j.jcmg.2020.02.019
   PubMed Web of Science ®Google Scholar
• Basiak M, Kosowski M, Cyrnek M, et al. Pleiotropic Effects of PCSK-9 Inhibitors. Int J Mol Sci. 2021 Mar 19;22(6):3144. doi: 10.3390/ijms22063144
   PubMed Web of Science ®Google Scholar
• Ma M, Hou C, Liu J. Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: focus on immune regulation. Front Cardiovasc Med. 2023;10:1148486. doi: 10.3389/fcvm.2023.1148486
   PubMed Web of Science ®Google Scholar
• Zhu L, Giunzioni I, Tavori H, et al. Loss of macrophage low-density lipoprotein receptor-related protein 1 confers resistance to the antiatherogenic effects of tumor necrosis factor-alpha inhibition. Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1483–1495. doi: 10.1161/ATVBAHA.116.307736
   PubMed Web of Science ®Google Scholar
• Canuel M, Sun X, Asselin MC, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One. 2013;8(5):e64145. doi: 10.1371/journal.pone.0064145
   PubMed Web of Science ®Google Scholar
• Scalise V, Sanguinetti C, Neri T, et al. PCSK9 induces tissue factor expression by activation of TLR4/NFkB signaling. Int J Mol Sci. 2021 Nov 23;22(23):12640. doi: 10.3390/ijms222312640
   PubMed Web of Science ®Google Scholar
• Artin J, Elsabagh YA, Rashed L, et al. Proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with diffuse systemic sclerosis: a marker of disease activity and severe disease manifestations with potential therapeutic implementations. Arch Rheumatol. 2023 Jun;38(2):249–256. doi: 10.46497/ArchRheumatol.2023.9638
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016 Dec 13;316(22):2373–2384. doi: 10.1001/jama.2016.16951
   PubMed Web of Science ®Google Scholar
• Ako J, Hibi K, Tsujita K, et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome　- the ODYSSEY J-IVUS trial. Circ J.2019 Sep 25;83(10):2025–2033. doi: 10.1253/circj.CJ-19-0412
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022 Jul;15(7):1308–1321. doi: 10.1016/j.jcmg.2022.03.002
   PubMed Web of Science ®Google Scholar
• Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022 May 10;327(18):1771–1781. doi: 10.1001/jama.2022.5218
   PubMed Web of Science ®Google Scholar
• Gupta K, Balachandran I, Foy J, et al. Highlights of cardiovascular disease prevention studies presented at the 2023 American college of cardiology conference. Curr Atheroscler Rep. 2023 Jun;25(6):309–321. doi: 10.1007/s11883-023-01103-4
   PubMed Web of Science ®Google Scholar
• de Isla L P, Diaz-Diaz JL, Romero MJ, et al. Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study. Circulation.2023 May 9;147(19):1436–1443. doi: 10.1161/CIRCULATIONAHA.122.062557
   PubMed Web of Science ®Google Scholar
• Rrapo-Kaso E, Loffler AI, Petroni GR, et al. Alirocumab and plaque volume, calf muscle blood flow, and walking performance in peripheral artery disease: A randomized clinical trial. Vasc Med. 2023 Aug;28(4):282–289. doi: 10.1177/1358863X231169324
   PubMed Web of Science ®Google Scholar
• Chen J, Zhao F, Lei C, et al. Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study. Front Pharmacol. 2022;13:999224. doi: 10.3389/fphar.2022.999224
   PubMed Web of Science ®Google Scholar
• Wu L, Kong Q, Huang H, et al. Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: a high-resolution MRI study. Front Aging Neurosci. 2023;15:1127534. doi: 10.3389/fnagi.2023.1127534
   PubMed Web of Science ®Google Scholar
• Akers EJ, Nicholls SJ, Di Bartolo BA. Plaque Calcification: Do Lipoproteins Have a Role? Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):1902–1910. doi: 10.1161/ATVBAHA.119.311574
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Xhaard C, Lamiral Z, et al. PCSK9 protein and rs562556 polymorphism are associated with arterial plaques in healthy middle-aged population: the STANISLAS cohort. J Am Heart Assoc. 2020 Apr 7;9(7):e014758. doi: 10.1161/JAHA.119.014758
   PubMed Web of Science ®Google Scholar
• Marfella R, Prattichizzo F, Sardu C, et al. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis. 2023 Aug;378:117180. doi: 10.1016/j.atherosclerosis.2023.06.971
   PubMed Web of Science ®Google Scholar
• Biccire FG, Haner J, Losdat S, et al. Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy. J Am Coll Cardiol. 2023 Oct 31;82(18):1737–1747. doi: 10.1016/j.jacc.2023.08.019
   PubMed Web of Science ®Google Scholar
• Karatasakis A, Danek BA, Karacsonyi J. et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017 Dec 9;6(12). doi: 10.1161/JAHA.117.006910
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713–1722. doi: 10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097–2107. doi: 10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation.2022 Oct 11;146(15):1109–1119. doi: 10.1161/CIRCULATIONAHA.122.061620
   PubMed Web of Science ®Google Scholar
• Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. Circulation.2018 Aug 21;138(8):756–766. doi: 10.1161/CIRCULATIONAHA.118.034309
   PubMed Web of Science ®Google Scholar
• Diaz R, Li QH, Bhatt DL, et al. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2021 Mar 23;28(1):33–43. doi: 10.1177/2047487320941987
   PubMed Web of Science ®Google Scholar
• Ogata A, Oho K, Matsumoto N, et al. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. Acta Neurochir (Wien). 2019 Mar;161(3):597–600. doi: 10.1007/s00701-019-03825-4
   PubMed Web of Science ®Google Scholar
• Huang YT, Ho LT, Hsu HY, et al. Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta-analysis. Front Pharmacol. 2022;13:832614. doi: 10.3389/fphar.2022.832614
   PubMed Web of Science ®Google Scholar
• Yu Z, Hu L, Sun C, et al. Effect of different types and dosages of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) levels: a network meta-analysis. J Cardiovasc Pharmacol. 2023 Jun 1;81(6):445–453. doi: 10.1097/FJC.0000000000001419
   PubMed Web of Science ®Google Scholar
• Zenti MG, Altomari A, Lupo MG, et al. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol. 2018 Nov;25(17):1843–1851 doi: 10.1177/2047487318792626
   PubMed Web of Science ®Google Scholar
• Ruscica M, Watts GF, Sirtori CR. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies. Eur J Prev Cardiol. 2019 Jun;26(9):998–1000. doi: 10.1177/2047487319833504
   PubMed Web of Science ®Google Scholar
• Ridker PM, Tardif JC, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with Bococizumab. N Engl J Med.2017 Apr 20;376(16):1517–1526. doi: 10.1056/NEJMoa1614062
   PubMed Web of Science ®Google Scholar
• Nishikido T. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2023 Jan 30;22(1):20. doi: 10.1186/s12933-023-01752-4
   PubMed Web of Science ®Google Scholar
• Chen PY, Gao WY, Liou JW, et al. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia. Int J Mol Sci. 2021 Jul 7;22(14):7310. doi: 10.3390/ijms22147310
   PubMed Web of Science ®Google Scholar
• Luo F, Das A, Khetarpal SA, et al. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Trends Cardiovasc Med. 2023 Feb 5. doi: 10.1016/j.tcm.2023.01.008
   Google Scholar
• Mohamed F, Mansfield BS, Raal FJ. ANGPTL3 as a drug target in hyperlipidemia and atherosclerosis. Curr Atheroscler Rep. 2022 Dec;24(12):959–967. doi: 10.1007/s11883-022-01071-1
   PubMed Web of Science ®Google Scholar
• Burks KH, Basu D, Goldberg IJ, et al. Angiopoietin-like 3: An important protein in regulating lipoprotein levels. Best Pract Res Clin Endocrinol Metab. 2023 May;37(3):101688 doi: 10.1016/j.beem.2022.101688
   PubMed Web of Science ®Google Scholar
• Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med.2020 Aug 20;383(8):711–720. doi: 10.1056/NEJMoa2004215
   PubMed Web of Science ®Google Scholar
• Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015 Jul;56(7):1308–17 doi: 10.1194/jlr.M054890
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017 Jul 20;377(3):211–221. doi: 10.1056/NEJMoa1612790
   PubMed Web of Science ®Google Scholar
• Fazio S, Minnier J, Shapiro MD, et al. Threshold effects of circulating angiopoietin-like 3 levels on plasma lipoproteins. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3340–3348. doi: 10.1210/jc.2016-4043
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023 Mar;29(3):729–737. doi: 10.1038/s41591-023-02222-w
   PubMed Web of Science ®Google Scholar
• Kleindorfer DO, Towfighi A, Chaturvedi S, et al. Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart association/American stroke association. Stroke. 2021 Jul;52(7):e364–e467. doi: 10.1161/STR.0000000000000375
   PubMed Web of Science ®Google Scholar
• Parikh NS, Merkler AE, Iadecola C. Inflammation, autoimmunity, infection, and stroke: epidemiology and lessons from therapeutic intervention. Stroke. 2020 Mar;51(3):711–718. doi: 10.1161/STROKEAHA.119.024157
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med.2017 Sep 21;377(12):1119–1131. doi: 10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med.2019 Feb 21;380(8):752–762. doi: 10.1056/NEJMoa1809798
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and Stroke Risk: A New Target for Prevention. Stroke. 2021 Aug;52(8):2697–2706. doi: 10.1161/STROKEAHA.121.034388
   PubMed Web of Science ®Google Scholar
• Puig N, Sole A, Aguilera-Simon A, et al. Novel therapeutic approaches to prevent atherothrombotic ischemic stroke in patients with carotid atherosclerosis. Int J Mol Sci. 2023 Sep 20;24(18):14325. doi: 10.3390/ijms241814325
   PubMed Web of Science ®Google Scholar